Cargando…

Classification of Clear Cell Renal Cell Carcinoma based on Tumor Suppressor Genomic Profiling

Clear cell renal cell carcinoma (ccRCC) is the most prevalent type of malignancy in adults. However, the clinical significance of tumor suppressor genes (TSG) is largely elusive. Herein, the expression profile TSGs and its clinical response in ccRCC were investigated. A total of 603 ccRCC samples fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Weimin, Zhang, Fengling, Huang, Chaoqun, Lin, Yao, Huang, Jiyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7974878/
https://www.ncbi.nlm.nih.gov/pubmed/33758612
http://dx.doi.org/10.7150/jca.50462
_version_ 1783666941224812544
author Zhong, Weimin
Zhang, Fengling
Huang, Chaoqun
Lin, Yao
Huang, Jiyi
author_facet Zhong, Weimin
Zhang, Fengling
Huang, Chaoqun
Lin, Yao
Huang, Jiyi
author_sort Zhong, Weimin
collection PubMed
description Clear cell renal cell carcinoma (ccRCC) is the most prevalent type of malignancy in adults. However, the clinical significance of tumor suppressor genes (TSG) is largely elusive. Herein, the expression profile TSGs and its clinical response in ccRCC were investigated. A total of 603 ccRCC samples from two cohorts (TCGA and ICGC) were retrieved in this study. Three molecular subtypes (C1, C2, and C3) were identified based on the TSGs expression profile in the TCGA dataset. Through Weighted Gene Correlation Network Analysis (WGCNA), six modules associated with three subtypes were identified. Pathway enrichment for the modules revealed that crucial pathways including p53 signaling and immune-related pathways were significantly enriched. We further focused on the relationship between immune infiltration level and subtypes, and found that subtype C1 was associated with higher immune infiltration level, subtype C2 was corresponding with medium immune infiltration level, whereas subtype C3 was correlated with lower immune infiltration level. Interestingly, C2 have a better survival outcome, while C1 and C3 showed a poor prognosis. Considering their survival difference, we then performed a differentially expression analysis between C2 and C1&3, and a total of 99 differentially expressed tumor suppressor genes (DETSGs) were identified. According to these DETSGs, 59 potential compounds with 28 mechanisms of action (MOA) were predicted using the Connectivity Map (CMap) database. Among these compounds, leflunomide, naftopidil, and ribavirin were the most prospective compounds for the treatment of ccRCC. In addition, we found that subtype C2 is more sensitive to sorafenib and sunitinib drugs, and C2 have more likelihood to be responded to immunotherapy. In summary, the three subtypes hinged on the tumor suppressor gene expression for ccRCC might contribute to understanding the underlying molecular mechanisms of ccRCC. Also, its potential compounds might offer guidelines for developing a novel treatment strategy of ccRCC.
format Online
Article
Text
id pubmed-7974878
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-79748782021-03-22 Classification of Clear Cell Renal Cell Carcinoma based on Tumor Suppressor Genomic Profiling Zhong, Weimin Zhang, Fengling Huang, Chaoqun Lin, Yao Huang, Jiyi J Cancer Research Paper Clear cell renal cell carcinoma (ccRCC) is the most prevalent type of malignancy in adults. However, the clinical significance of tumor suppressor genes (TSG) is largely elusive. Herein, the expression profile TSGs and its clinical response in ccRCC were investigated. A total of 603 ccRCC samples from two cohorts (TCGA and ICGC) were retrieved in this study. Three molecular subtypes (C1, C2, and C3) were identified based on the TSGs expression profile in the TCGA dataset. Through Weighted Gene Correlation Network Analysis (WGCNA), six modules associated with three subtypes were identified. Pathway enrichment for the modules revealed that crucial pathways including p53 signaling and immune-related pathways were significantly enriched. We further focused on the relationship between immune infiltration level and subtypes, and found that subtype C1 was associated with higher immune infiltration level, subtype C2 was corresponding with medium immune infiltration level, whereas subtype C3 was correlated with lower immune infiltration level. Interestingly, C2 have a better survival outcome, while C1 and C3 showed a poor prognosis. Considering their survival difference, we then performed a differentially expression analysis between C2 and C1&3, and a total of 99 differentially expressed tumor suppressor genes (DETSGs) were identified. According to these DETSGs, 59 potential compounds with 28 mechanisms of action (MOA) were predicted using the Connectivity Map (CMap) database. Among these compounds, leflunomide, naftopidil, and ribavirin were the most prospective compounds for the treatment of ccRCC. In addition, we found that subtype C2 is more sensitive to sorafenib and sunitinib drugs, and C2 have more likelihood to be responded to immunotherapy. In summary, the three subtypes hinged on the tumor suppressor gene expression for ccRCC might contribute to understanding the underlying molecular mechanisms of ccRCC. Also, its potential compounds might offer guidelines for developing a novel treatment strategy of ccRCC. Ivyspring International Publisher 2021-02-22 /pmc/articles/PMC7974878/ /pubmed/33758612 http://dx.doi.org/10.7150/jca.50462 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Zhong, Weimin
Zhang, Fengling
Huang, Chaoqun
Lin, Yao
Huang, Jiyi
Classification of Clear Cell Renal Cell Carcinoma based on Tumor Suppressor Genomic Profiling
title Classification of Clear Cell Renal Cell Carcinoma based on Tumor Suppressor Genomic Profiling
title_full Classification of Clear Cell Renal Cell Carcinoma based on Tumor Suppressor Genomic Profiling
title_fullStr Classification of Clear Cell Renal Cell Carcinoma based on Tumor Suppressor Genomic Profiling
title_full_unstemmed Classification of Clear Cell Renal Cell Carcinoma based on Tumor Suppressor Genomic Profiling
title_short Classification of Clear Cell Renal Cell Carcinoma based on Tumor Suppressor Genomic Profiling
title_sort classification of clear cell renal cell carcinoma based on tumor suppressor genomic profiling
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7974878/
https://www.ncbi.nlm.nih.gov/pubmed/33758612
http://dx.doi.org/10.7150/jca.50462
work_keys_str_mv AT zhongweimin classificationofclearcellrenalcellcarcinomabasedontumorsuppressorgenomicprofiling
AT zhangfengling classificationofclearcellrenalcellcarcinomabasedontumorsuppressorgenomicprofiling
AT huangchaoqun classificationofclearcellrenalcellcarcinomabasedontumorsuppressorgenomicprofiling
AT linyao classificationofclearcellrenalcellcarcinomabasedontumorsuppressorgenomicprofiling
AT huangjiyi classificationofclearcellrenalcellcarcinomabasedontumorsuppressorgenomicprofiling